/Investor DB

Axil Capital

Venture capital

Tokyo · Seed–Growth · 12 people tracked

Find your way into Axil Capital

Sign up to see every warm intro you have to Axil Capital

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Axil Capital team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

Axil Capital is a global venture capital firm focused on the life sciences, backing founders and companies in biomedical and healthcare technology. It invests across regions, subsectors, and stages, from seed through crossover, supporting companies advancing medical care and life-science innovation. The firm combines venture capital, finance, and deep scientific expertise, and provides its global network and resources to help ambitious teams advance breakthrough science and transformational technology shaping the future of medical care.

Source: firm website, verified Nov 8, 2026.

Stage
Seed–Growth
HQ
Tokyo, JP
Instruments
Equity
Founded
2017
Tracked investments
30

Team · 12 people

from the firm's website & curated & public directories
Fred Shane· Managing Partner

Co-founder of Axil Capital (2017) who leads the global investment team and manages its global portfolio. Previously a Director in the Investment Business Department at Mizuho Securities and set up biotech investment operations at Marubeni USA; holds a BS in Electrical Engineering & Computer Science from MIT.

Hiroshi Gonaikawa· Partnerin

Co-founder of Axil Capital (2017) who heads the domestic investment team and manages its domestic portfolio. Has nearly 40 years in investment banking, VC and consulting, starting at Nomura Research Institute and later launching a VC fund at Nomura Securities; holds a BS in Economics from Tohoku University.

Joon Paek· Principal

Principal who joined Axil in 2020, focused on deal flow and building value in portfolio companies. Previously spent nearly 15 years at cell therapy ventures including Metcela and Tissue Genesis and started as a chemical engineer at NASA Langley; holds a PhD from Brown and an MBA from Waseda.

Kimihito Usui· Senior Principalin

Kimihito Usui is a Senior Principal at Axil Capital Partners (Axil Capital Advisors K.K.), focusing on early-stage biotech investment across the US, Japan, and Taiwan. He holds a Ph.D. in pharmaceutical sciences from the University of Tokyo and worked as a researcher on artificial cell models and later as a lead researcher at a drug discovery venture, where he handled preclinical study design, budget management, fundraising, and business development, publishing 12 peer-reviewed papers. Since 2016 he has worked in life science and healthcare investment, establishing his firm's first direct biotech investment scheme in a securities-based principal investment division and completing direct investments in nine companies across the US and Japan, two of which listed on NASDAQ.

Yuji Onizawa· Principal

Principal focused on sourcing, evaluation and execution of biopharma and medtech investments. Previously spent over a decade in preclinical drug discovery at Eisai and later led portfolio strategy and alliance management there; holds a PhD in Organic Synthetic Chemistry from Tokyo Institute of Technology.

Akihisa Seita· Principalin

Principal who joined Axil in 2019, focused on sourcing, evaluation and execution of biotech and medtech investments. Formerly a postdoctoral researcher at the University of Tokyo; holds a PhD specializing in quantitative and single-cell biology and is an FMI-certified Advanced Financial Modeler.

Kenji Maekubo· Principalin

Principal who joined Axil in 2018, focused on sourcing, evaluation and execution of biotech and medtech investments. Previously worked at a life-science recruitment firm; holds an MS in developmental biology from Kwansei Gakuin University and is an FMI-certified Advanced Financial Modeler.

Yoshitake Maeda· Venture Partner

Joined Axil in 2023 with over 20 years in pharmaceutical R&D and business development. Previously Director of Search & Evaluation for Japan & Asia at Bristol-Myers Squibb and held roles at Kyowa Hakko Kirin and Kirin Brewery; holds a PhD in Pharmaceutical Sciences from Kyushu University.

Rick Tsai· Venture Partnerin

Venture Partner handling technical due diligence and strategic advisory to portfolio companies, and former CEO of portfolio company LUCA Science. Previously an oral and maxillofacial surgeon and held leadership roles at Banyu Pharmaceutical, MSD and Allergan; holds a DMD from Harvard and an MD from Columbia.

Itaru Hasegawa· Head of Compliance & Administration

Oversees Axil Capital's compliance, legal and corporate administration, with over four decades in Japan's asset-management industry. Previously managed equity portfolios at Yasuda Fire and Marine Insurance and held senior corporate and compliance roles at Franklin Templeton Japan and other firms.

Miyuki Kamei· Office Manager

Office Manager handling administrative matters across Axil Capital, with the firm since its 2017 founding.

Tetsuji Nakajima· Manager of IT

Manages Axil Capital's IT systems and infrastructure. Began as a production engineer at an electric-wire manufacturer before founding his own software company; holds a master's in Electrical Engineering from Kansai University.

What they invest in

from 12 of 30 portfolio companies

Biotech ×9Healthtech ×8Medical Devices ×5Deep Tech ×3Digital Health ×3AI & Machine Learning ×1Longevity ×1

HQs:Japan×4United States×3

Investments · 30 tracked

founders shown can be your intro path

By year:2021 · 22020 · 12019 · 14 dated

Abrax Japan, Inc.abrax-japan.com

Abrax develops therapeutic drugs targeting skin and lipid disorders, aiming to commercialize discoveries from academic immunology research.

BiotechHealthtech

上林拓(Co-founder & CSA)成田譲(Co-founder & CEO)

Ascendo Biotechnology, Inc.ascendobiotech.com

Ascendo Biotechnology is a clinical-stage biopharmaceutical company developing innate immune checkpoint therapies for cancer and autoimmune disease.

BiotechHealthtech

DT-Axis Co., Ltd.dt-axis.co.jp

DT Axis develops digital therapeutics (DTx) and software as a medical device (SaMD), including evidence-based treatment apps for conditions such as depression.

Digital HealthHealthtechMedical Devices

Elixiron Immunotherapeutics Inc.elixiron.com

Elixiron Immunotherapeutics develops precision immunotherapies for neuroinflammation, autoimmune diseases, and cancer, with two clinical-stage candidates: EI-1071 (Enrupatinib) for Alzheimer's, ALS, and Parkinson's, and EI-001 (Indemakitug) for vitiligo and alopecia areata.

BiotechHealthtech

Eurus Therapeutics Inc.eurus-tx.com

Eurus Therapeutics develops genetic medicines using its genome integration technology, which inserts large DNA cargos at specific sites without nuclease-mediated DNA cleavage for durable therapeutic expression.

BiotechDeep TechMedical Devices

Takato Noumi(Founder & CEO)Naoki Inoue(COO)Ryo Arashida(Vice President, IP Strategy)

Co-investorsKyoto University Innovation Capital

Fore Biotherapeuticsfore.bioin𝕏

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsHBM Healthcare InvestmentsHBM PartnersLG Technology VenturesNovartis Venture FundOrbiMedPontifax Venture Capital+5 more

Jolly Good Inc.jollygoodinc.com

Jolly Good develops medical and welfare VR solutions, including a subscription platform for digital health VR content, self-production tools using high-precision VR cameras, and VR-based digital therapeutics.

Digital HealthHealthtechMedical Devices

LUCA Scienceluca-science.comSeries A · Sep 2020 · $10M

LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.

BiotechDeep TechHealthtechLongevity

Co-investorsAsahi Kasei Corporate Venture CapitalFast Track InitiativeRemiges Ventures, Inc.4BIO CapitalAstellas Venture Management LLCDCI Partners Co. Ltd.

MabGenesismabgenesis.com

MabGenesis is a Japanese startup biopharmaceutical company that commercializes decades of academic antibody research to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and animal use.

BiotechDeep TechHealthtech

Co-investorsBeyond Next VenturesLong Black Partners

Suono Biosuonobio.cominJul 2021

BiotechMedford, US

Giovanni Traverso(Director)inRobert Langer(Director)Carl Schoellhammer(Executive Officer, Director)inAmy Schulman(Director)

Co-investorsTaiwania Capital

TechsoMedtechsomed.cominMar 2021 · $7M

TechsoMed develops BioTrace, an FDA-cleared software platform for image-guided minimally invasive cancer therapy that uses AI to provide real-time 3D visualization, tumor margin control, needle path planning, and post-ablation tissue response prediction.

AI & Machine LearningDigital HealthMedical Devices

Co-investorsNextLeap VenturesHelios Climate Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Allgenesis Biotherapeutics, Inc.Allterum Therapeutics, Inc.Angiocrine Bioscience Inc.C4 Therapeutics Inc.Cellusion Inc.Cranebio Co., Ltd.CynosBio, Inc.Frequency TherapeuticsGEXVal Inc.Himuka AM Pharma Corp.HoneyBear Biosciences, Inc.LinqMed, Inc.Perseus Proteomics Inc.Pulmotect, Inc.Rakuten Medical, Inc.Syncell, Inc.TechsoMed Medical Technologies Ltd.United Immunity Co., Ltd.Y4.com Co., Ltd.

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has Axil Capital made?
Axil Capital has 30 tracked investments.
What stage does Axil Capital invest at?
Axil Capital invests at the Seed, Series A, Series B, Series C, Growth stages.
What sectors does Axil Capital focus on?
Axil Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is Axil Capital located?
Axil Capital is headquartered in Tokyo, JP.
Does Axil Capital lead rounds?
Axil Capital has led 3 of the 3 rounds where its role is on record.
Who does Axil Capital co-invest with?
Axil Capital most often shares deals with LG Technology Ventures, Novartis Venture Fund, OrbiMed, among 14 tracked co-investors.

Images

Axil Capital photo

Co-investors · 2

Astellas Venture Management LLC

Astellas Venture Management LLC is the venture capital arm associated with Astellas, investing in biotechnology and therapeutics companies developing novel drug modalities and cell/gene therapy platforms.

Both backed · 1
$200K – $5M
Remiges Ventures, Inc.

Remiges Ventures is a venture capital firm focused on life sciences and drug discovery, and runs an incubation fund (RDiscovery Fund) for early-stage drug discovery seeds.

Both backed · 1

Firms observed investing alongside Axil Capital, from public investor directories. Shared companies are the overlap with Axil Capital's recorded portfolio.

Similar investors

Featured in lists